drugset / Trial / NCT01168401

Bivalent Norovirus Vaccine Study

NCT01168401 ↗

Phase 1 Completed 102 enrolled Takeda
RandomizedParallel-groupTriple-blindPrevention

Summary

Randomized, multi-site, dose-escalation study of the safety and immunogenicity of four dosage levels of Intramuscular (IM) Norovirus Bivalent VLP Vaccine adjuvanted with MPL and Al(OH)3 compared to controls. Participants will receive two doses, by IM injection, 28 days apart. The hypotheses for this study are: * The incidence of adverse events after vaccination with IM Norovirus Bivalent VLP Vaccine will be similar to the incidence of adverse events after other IM vaccines including CERVARIX® which contains MPL and Al(OH)3. * Two doses of IM Norovirus Bivalent VLP Vaccine will be more immunogenic than one dose. * The post-vaccination serum antibody responses, the number of antibody secreting cells (ASC), including homing markers, and memory B-cell responses directed against norovirus antigens will be increased after IM Norovirus Bivalent VLP Vaccine compared to controls.

Timeline

Start
2010-09-03
Primary completion
2013-01-01
Completion
2013-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NoV GI.1/GII.4 Bivalent VLP Vaccine Vaccine 5 ug Intramuscular
Subject NoV GI.1/GII.4 Bivalent VLP Vaccine Vaccine 15 ug Intramuscular
Subject NoV GI.1/GII.4 Bivalent VLP Vaccine Vaccine 50 ug Intramuscular
Subject NoV GI.1/GII.4 Bivalent VLP Vaccine Vaccine 150 ug Intramuscular

Indications